Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C76H104N18O19S2 |
Molecular Weight | 1637.8833 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 15 / 15 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1(NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@]([H])(NC(=O)[C@H](CC6=CC=CC=C6)NC1=O)[C@@H](C)O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
InChI
InChIKey=NHXLMOGPVYXJNR-ATOGVRKGSA-N
InChI=1S/C76H104N18O19S2/c1-41(79)64(100)82-37-61(99)83-58-39-114-115-40-59(76(112)113)92-72(108)57(38-95)91-75(111)63(43(3)97)94-71(107)54(33-46-23-11-6-12-24-46)90-74(110)62(42(2)96)93-66(102)51(28-16-18-30-78)84-69(105)55(34-47-36-81-49-26-14-13-25-48(47)49)88-68(104)53(32-45-21-9-5-10-22-45)86-67(103)52(31-44-19-7-4-8-20-44)87-70(106)56(35-60(80)98)89-65(101)50(85-73(58)109)27-15-17-29-77/h4-14,19-26,36,41-43,50-59,62-63,81,95-97H,15-18,27-35,37-40,77-79H2,1-3H3,(H2,80,98)(H,82,100)(H,83,99)(H,84,105)(H,85,109)(H,86,103)(H,87,106)(H,88,104)(H,89,101)(H,90,110)(H,91,111)(H,92,108)(H,93,102)(H,94,107)(H,112,113)/t41-,42+,43+,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,62-,63-/m0/s1
Molecular Formula | C76H104N18O19S2 |
Molecular Weight | 1637.8833 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 15 / 15 |
E/Z Centers | 4 |
Optical Activity | UNSPECIFIED |
Somatostatin (also known as growth hormone-inhibiting hormone) is a naturally-occurring peptide hormone that regulates the endocrine system. Somatostatin is produced in gastrointestinal (GI) tract, pancreas, hypothalamus, and central nervous system (CNS) and some other organs. Somatostatin is initially secreted as a 116 amino acid precursor, preprosomatostatin, which undergoes endoproteolytic cleavage to prosomastatin. Prosomastatin is further process into two active forms, shorter isoform somatostatin-14 works primarily in the brain, while the longer somatostatin-28 (SST-28) form operates in the GI tract. Somatostatin produces predominantly neuroendocrine inhibitory effects across multiple systems. It is known to inhibit GI, endocrine, exocrine, pancreatic, and pituitary secretions, as well as modify neurotransmission and memory formation in the CNS. Somatostatin binds to six different receptors in various systems and cells throughout the body to produce its regulatory effect. These receptors are specific to somatostatin and classify as G-protein coupled receptors (GPCR). Somatostatin half-life is between 1 to 3 minutes. Due to its short half-life, somatostatin has been formulated exogenously in much more stable forms with a longer half-life; this allows for its primary clinical use, which is the treatment of neuroendocrine tumors.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Effects of mexiletine on algogenic mediator-induced nociceptive responses in mice. | 1999 Jul-Aug |
|
G protein beta interacts with the glucocorticoid receptor and suppresses its transcriptional activity in the nucleus. | 2005 Jun 20 |
|
Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells. | 2008 Jul |
|
Design, synthesis, and evaluation of novel 3,6-diaryl-4-aminoalkoxyquinolines as selective agonists of somatostatin receptor subtype 2. | 2011 Apr 14 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 17:17:26 GMT 2025
by
admin
on
Wed Apr 02 17:17:26 GMT 2025
|
Record UNII |
6E20216Q0L
|
Record Status |
FAILED
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
21587
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
||
|
FDA ORPHAN DRUG |
86094
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
||
|
LOINC |
2960-3
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
||
|
LOINC |
49792-5
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
||
|
WHO-VATC |
QH01CB01
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
||
|
WHO-ATC |
H01CB01
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
||
|
LOINC |
2961-1
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6E20216Q0L
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
PRIMARY | |||
|
51110-01-1
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
NO STRUCTURE GIVEN | |||
|
100000092022
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
PRIMARY | |||
|
DB09099
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
PRIMARY | |||
|
2997
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
PRIMARY | |||
|
CHEMBL1823872
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
PRIMARY | |||
|
38916-34-6
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
PRIMARY | |||
|
SUB12320MIG
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
PRIMARY | |||
|
m10111
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
PRIMARY | Merck Index | ||
|
16129706
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
PRIMARY | |||
|
4311
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
PRIMARY | |||
|
64628
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
PRIMARY | |||
|
254-186-5
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
PRIMARY | |||
|
DTXSID8046793
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
PRIMARY | |||
|
9939
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
PRIMARY | RxNorm | ||
|
256-969-7
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
ALTERNATIVE | |||
|
D013004
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
PRIMARY | |||
|
C836
Created by
admin on Wed Apr 02 17:17:26 GMT 2025 , Edited by admin on Wed Apr 02 17:17:26 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
DERIVATIVE -> PARENT |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
AGONIST -> TARGET |
|
||
|
INDUCER -> TARGET |
ACTIVATES RELEASE OF SOMATOSTAIN
|
||
|
INGREDIENT -> STARTING MATERIAL |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
DERIVATIVE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|